Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Top Drug Official in China Faces Music (China)

This article was originally published in PharmAsia News

Executive Summary

Former drug registration official Cao Wenzhuang is the third senior official with China's State Food and Drug Administration to go on trial, as his trial starts for charges of corruption and dereliction of duty. Cao, charged with taking 2.34 million yuan in bribes, has denied the charges. He was also charged with lowering the drug registration standards. Cao's former boss, Zheng Xiaoyu, was sentenced to death in May. Hao Heping, also one of Zheng's former secretaries, was sentenced to 15 years in prison on corruption charges last November. (Click here for more

You may also be interested in...



Deals Shaping The Medical Industry, April 2020

This month’s column covers deals announced between 1-23 April 2020. 

EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR - How To Survive Changing And Confusing Times

May 26 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.

Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel